Press Release 21 February 2000 – British Lung Foundation

The exploration of a brand-new approach to provide gene therapy securely could have a major impact on the growth of hereditary techniques to deal with usual lung illness such as cystic fibrosis, asthma and also lung cancer cells.
Until now, there has actually not been an effective way to introduce therapeutic genes into cells efficiently without causing potentially fatal swelling. This has actually prevented the improvement of lifesaving therapies.

The study, released today in ‘Genetics Therapy’, was performed by researchers at University University London (UCL) and moneyed by the British Lung Structure, Arthritis Research Project as well as the Wellcome Depend on.
Lead scientist, Medical professional Stephen Hart explains: “Gene treatment opens the chance to create new methods to treating acquired diseases. The major restriction currently is the lack of a safe, reliable technique for inserting restorative genetics into the cells and body organs impacted by the condition. We have developed a novel artificial system that has great possible for delivering genes right into the lung. We are nearer than ever to treating conditions which presently are incurable.”

Scientists believe that genetics therapy holds the vital to dealing with lots of incurable and harmful diseases, such as cystic fibrosis, which influences 7,000 youths in this country. But their progression has actually been prevented by ineffective and also high-risk methods.

There are presently two techniques of introducing healing genes into the body. One uses a virus, yet causes possibly deadly inflammation of the treated location. The other, much safer technique, binds genes to harmless fatty liposomes, but the results are not extremely satisfactory.

The UCL researchers have designed an advanced procedure of introducing restorative genetics right into the lung in a manner that functions more efficiently, without triggering swelling. They have actually improved the liposome technique by adding peptide – a small protein – to the gene shipment mixture. Preliminary lab trials have actually currently shown very successful.

Chief Executive of the British Lung Foundation, Bengie Walden commented: “Advancements of this kind mean we are ever closer to being able to treat the millions of individuals that experience crippling lung problems. We are really pleased to have actually moneyed this leading-edge research and also delighted with the outcomes thus far”.

– Ends-.
For more information, please call Jo Blake or Caroline Ward on 020 7439 7177.
Notes to Editors:.
· The British Lung Foundation is the only charity in the UK increasing funds for necessary research study into the avoidance, medical diagnosis, treatment as well as treatment of all lung illness.

Back to Information.